Compare GFR & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GFR | DRTS |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | Canada | Israel |
| Employees | 197 | 121 |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 713.7M | 641.6M |
| IPO Year | N/A | N/A |
| Metric | GFR | DRTS |
|---|---|---|
| Price | $5.94 | $9.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 245.7K | ★ 607.6K |
| Earning Date | 05-05-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $699.98 |
| P/E Ratio | $4.33 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.10 | $2.81 |
| 52 Week High | $7.02 | $10.80 |
| Indicator | GFR | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 46.52 | 64.89 |
| Support Level | $5.64 | $6.59 |
| Resistance Level | $6.24 | N/A |
| Average True Range (ATR) | 0.30 | 0.77 |
| MACD | -0.04 | 0.21 |
| Stochastic Oscillator | 32.80 | 69.04 |
Greenfire Resources Ltd explores, acquires, develops and produces oil and gas in the Canadian energy sector and internationally. Greenfire currently has two producing oil sand assets, Hangingstone Expansion and Hangingstone Demo. The company has one reportable operating segment which is made up of its oil sands operations based on geographic location : Athabasca oil sands region of Alberta, Canada, nature of the products sold and integration of facilities and operations. The company is actively developing its Hangingstone Facilities using SAGD, an enhanced oil recovery extraction method.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.